Avivagen Scientists Publish Supporting Evidence about Natural Alternative to Antibiotic Use in Livestock
ACCESSWIRE - Fri Oct 31, 1:05PM CDT
Ottawa, ON / ACCESSWIRE / October 31, 2014 / Today the leading journal PLOS ONE published research that provides underlying scientific support for a fundamentally new type of natural alternative to the use of antibiotics in livestock feeds for growth promotion and disease prevention. The paper is the result of work by both independent and company scientists. Avivagen Inc. (TSXV: VIV, OTC Pink: CHEXF) is a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them.
Avivagen Announces Launch of New Corporate Website
ACCESSWIRE - Tue Oct 14, 7:11AM CDT
Ottawa, ON / ACCESSWIRE / October 14, 2014 / Avivagen Inc. (TSXV: VIV, OTC Pink: CHEXF), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces the launch of its new corporate website.
Avivagen Announces Feature Article on OXC-Beta Swine Results in Ontario Hog Farmer's Magazine
ACCESSWIRE - Thu Oct 02, 7:12AM CDT
Ottawa, ON / ACCESSWIRE / October 2, 2014 / Avivagen Inc. (TSXV: VIV, OTC Pink: CHEXF), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces the publication of a trade magazine article about the use of OxC-beta in Canadian swine.
Avivagen Announces CEO Update & Preliminary Study Results
ACCESSWIRE - Thu Sep 25, 7:09AM CDT
Ottawa, ON / ACCESSWIRE / September 25, 2014 / Avivagen Inc. (TSXV: VIV, OTC Pink: CHEXF), a wellness company developing and delivering products that support and enhance the health and quality of life of animals and the people who care for them, announces the release and website posting of a CEO update letter that includes a discussion of the preliminary results from two Asian livestock studies. In addition to reading the contents of the CEO update letter below, we encourage you to visit the Avivagen website to learn more about the company, at www.avivagen.com.
Avivagen Commences Study on Permanent and Non-Surgical Sterilization Technology
ACCESSWIRE - Wed Aug 13, 7:03AM CDT
Ottawa, ON / ACCESSWIRE / Aug 13 2014 / Avivagen Inc. (TSXV: VIV, OTC Pink: CHEXF), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces the start of a proof-of-concept study on its optioned technology for the permanent sterilization of female mammals - that may eliminate the need for surgical spaying.
Avivagen Announces Aquaculture Trial Agreement With Nam Sai Farms of Thailand
ACCESSWIRE - Fri Jul 18, 7:03AM CDT
Ottawa, ON / ACCESSWIRE / Jul 18 2014 / - Avivagen Inc. (TSXV: VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, today announced an agreement with Nam Sai Farms Co. Ltd. of the Kingdom of Thailand to conduct a trial to determine the effects of OxC-beta on the grow-out parameters of tilapia.
VIV.VN: 0.060 (+0.005)
Avivagen Announces Investor Conference Attendance In British Columbia, Canada July 17-19
ACCESSWIRE - Wed Jul 16, 9:17AM CDT
Ottawa, ON / ACCESSWIRE / Jul 16 2014 / - Avivagen Inc. (TSXV: VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces that it will be attending an investor conference in the Canadian province of British Columbia.
VIV.VN: 0.060 (+0.005)
Avivagen Options Technology for Permanent and Non-Surgical Sterilization of Female Mammals
ACCESSWIRE - Thu Jul 10, 7:03AM CDT
Ottawa, ON / ACCESSWIRE / July 10 2014 / Avivagen Inc. (TSXV: VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces it has entered into an option to acquire an exclusive license to a technology for the permanent sterilization of female mammals - that may eliminate the need for surgical spaying.
VIV.VN: 0.060 (+0.005)
Avivagen Announces Poultry Trial Agreement with Chonbuk National University of Korea
ACCESSWIRE - Mon Mar 31, 7:05AM CDT
Ottawa, ON / ACCESSWIRE / March 31, 2014 / Avivagen Inc. (TSXV: VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces an agreement with Chonbuk National University of the Republic of Korea (South Korea) to conduct a trial of OxC-beta for the prevention of a commercially important poultry disease.
VIV.VN: 0.060 (+0.005)
Avivagen Announces Swine Trial Agreement with National Institute of Animal Sciences for Vietnam
ACCESSWIRE - Tue Mar 25, 7:21AM CDT
OTTAWA, ON / ACCESSWIRE / March 25, 2014 / Avivagen Inc. (TSXV: VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces an agreement with the National Institute of Animal Sciences for Vietnam to conduct a trial of OxC-beta as a non-antibiotic growth promoter for swine.
VIV.VN: 0.060 (+0.005)
Avivagen Announces CEO Update Letter
ACCESSWIRE - Mon Mar 17, 7:12AM CDT
Ottawa, ON / Accesswire / Mar 17 2014 / - Avivagen Inc. (TSXV:VIV), a wellness company developing and delivering products that support and enhance the health and quality of life of animals and the people who care for them, announces the release and website posting of a CEO update letter. In addition to reading the contents of the CEO update letter below, we encourage you to visit the Avivagen website to learn more about the company, at www.avivagen.com.
VIV.VN: 0.060 (+0.005)